Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: Results from two 12-month randomized studies

Clinical Endocrinology

Volumn 57, Issue 2, 2002, Pages 273-281

  Abrahamsen, B ^a   Hangaard, J ^a   Horn, H C ^a   Hansen, T B ^a   Gregersen, G ^b   Hansen Nord, M ^a   Vahl, N ^c   Junker, P ^a   Andersen, M ^a   Hagen, C ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b Esbjerg Central Hospital   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 1 TELOPEPTIDE; COLLAGEN TYPE 3; GROWTH HORMONE; HUMAN GROWTH HORMONE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE REMODELING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; EVALUATION; FEMALE; FOLLOW UP; FOREARM; GROWTH HORMONE DEFICIENCY; HIP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SOFT TISSUE; SPINE; TUMOR RECURRENCE;

ADENOMA; ADULT; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; COLLAGEN; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PITUITARY NEOPLASMS; PROCOLLAGEN;

EID: 0036359122     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2002.01582.x     Document Type: Article

References (26)

1. The pyridostigmine-growth-hormone-releasing-hormone test in adults. The reference interval and a comparison with the insulin tolerance test
2. The influence of growth hormone on cancellous and cortical bone of the vertebral body in aged rats
3. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial
4. The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults
5. The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism
6. The effect of growth hormone (GH) on histomorphometric indices of bone structure and bone turnover in GH-deficient men
7. Does growth hormone therapy in adult patients with growth hormone deficiency protect against bone loss?
8. Growth hormone treatment in adults with adult-onset growth hormone deficiency increases iliac crest trabecular bone turnover: A 1-year, double-blind, randomized, placebo-controlled study
9. The effects of gonadotrophin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis
10. Reduced bone mineral density in adults with growth hormone (GH) deficiency: Increased bone turnover during 12 months of GH substitution therapy
11. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II
12. Influence of fat on bone measurements with dual-energy absorptiometry
13. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: A double blind, randomized, placebo-controlled study
14. Whole body and regional soft tissue changes in growth hormone deficient adults after one year of growth hormone treatment: A double-blind, randomized, placebo-controlled study
15. The bone-remodeling transient: Implications for the interpretation of clinical studies of bone mass change
16. Interpreting trials of bone-active agents
17. Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency
18. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency
19. Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency
20. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: Relation to age, sex, stage of puberty, testicular size, and body mass index
21. Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults
22. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients
23. Increased fracture rate in adults with growth hormone deficiency
24. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults
25. Short- and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males
26. Growth hormone treatment of adults with growth hormone deficiency: Results of a 13-month placebo controlled cross-over study